Accelrys

What Accelrys does

Accelrys was a San Diego-headquartered scientific informatics software company founded in the late 1980s (originally as a platform enabling researchers in life sciences, chemicals, and materials to manage scientific data, automate workflows, and run computational modeling). Its core technology stack centered on products such as Pipeline Pilot for scientific workflow automation, Discovery Studio and Materials Studio for molecular and materials modeling, ONE Lab for laboratory execution, and electronic laboratory notebooks for regulated R&D environments. The company built capabilities through multiple acquisitions of Symyx Technologies, Contur Software, VelQuest, Aegis Analytical, ChemSW, and Qumas, layering in lab informatics, quality management, and analytical data handling on top of its modeling core.

In April 2014 Accelrys was acquired by Dassault Systèmes and ceased to trade as a standalone public entity on NASDAQ (ticker ACCL). Its offerings are now sold under the BIOVIA brand within Dassault's 3DEXPERIENCE platform, covering molecular modeling, materials simulation, lab informatics, quality and regulatory compliance, and increasingly AI-driven scientific discovery. The 3DEXPERIENCE platform combines BIOVIA, CATIA, SOLIDWORKS, SIMULIA, and other 3D design / engineering / simulation applications, and BIOVIA contributes the scientific R&D layer for industries including pharmaceuticals, biotechnology, chemicals, consumer goods, aerospace, and automotive.

The business model is enterprise B2B software: customers license BIOVIA modules on subscription or term basis, consume professional services for deployment and validation, and engage Dassault for ongoing support. Pricing is anchored to per-seat, per-site, or enterprise-wide agreements; revenue mechanics therefore depend heavily on multi-year enterprise contracts, large-account renewals, and validation-heavy regulated deployments. Leadership pedigree includes co-founder Alejandro Zaffaroni (a biotechnology entrepreneur and investor), co-founder Peter G. Schultz (a noted chemist), and former CEO Max Carnecchia; the company has historically emphasized GxP compliance, ISO certifications, and integration with enterprise LIMS/ERP/PLM systems. Customer concentration is moderate, with a roster of named enterprise users spanning Pfizer, AstraZeneca, Amgen, Bayer, Sanofi, Gilead, L'Oréal, P&G, Unilever, Airbus, GM, Tesla, Dow Chemical, and Aboca across pharmaceuticals, consumer goods, automotive, and chemicals. In 2025, BIOVIA announced a strategic partnership with NVIDIA to integrate accelerated computing and inference technology into BIOVIA Scientific AI, alongside new offerings including AI-Ready Lab, AI-Powered Formulation Development, Generative Therapeutics Design, and Virtual Twin Experiences, positioning the platform for the growing enterprise scientific AI market. However, as a fully integrated subsidiary of a publicly traded French parent, BIOVIA does not separately disclose segmental revenue, headcount, or capital allocation, which limits standalone financial visibility. The company was originally venture-backed before its NASDAQ IPO and went through multiple funding and acquisition cycles prior to the Dassault transaction. The intellectual property estate is anchored by long-lived scientific algorithms including the COSMO-RS quantum-chemistry thermodynamics framework, continued development of which supports differentiation in formulation and process chemistry applications. Go-to-market remains primarily direct enterprise sales supplemented by an academic licensing program targeting universities to build long-term developer adoption of the BIOVIA stack. Geographic reach is global via Dassault Systèmes' commercial footprint, and the underlying computational biology and chemistry software market is in a structural growth phase driven by AI adoption in R&D. As of the most recent available inputs, named recent strategic actions have been the 2025 NVIDIA partnership and the 2025 AI product launches under the BIOVIA brand, with the 2014 Dassault acquisition remaining the single most consequential corporate event in Accelrys' history. No new standalone funding events, executive transitions, or divestitures are reported in the input beyond these events.

Name

Accelrys

Legal name

Accelrys Inc.

Website

https://accelrys.com

Company type

Private

Founded year

1987

Operating status

Acquired

Headcount range

501–1,000 employees

Short description

Accelrys, now operating as BIOVIA under Dassault Systèmes, provides enterprise scientific informatics software for life sciences, chemicals, and materials R&D, covering molecular modeling, lab informatics, and AI-driven discovery for large pharmaceutical, consumer goods, and industrial customers.

Ownership category

akta.pro rank

Product category

Scientific Informatics Software

NAICS

Software Publishers (513210), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Laboratory Informatics for Diagnostics (LIS/Middleware/Analyzer Connectivity) (HLAHAAAO), Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN)

Keywords

• Scientific informatics software
• Molecular modeling software
• Drug discovery platform
• Laboratory informatics
• Materials science simulation

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Software Licenses and Subscriptions: BIOVIA generates revenue primarily through software licensing and subscription fees for its scientific software portfolio including Discovery Studio, Materials Studio, Pipeline Pilot, and ONE Lab. Full versions require paid licenses with academic institutions eligible for discounted pricing. Free visualizer versions available for basic molecular structure viewing.
2. Professional Services: Dassault Systèmes provides services offerings including implementation, training, and consulting services for BIOVIA products.
3. Contract Research Services: BIOVIA offers contract research services providing specialized scientific research capabilities to clients.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels10 records

Core offering

Accelrys develops and licenses scientific informatics software and services for life sciences, chemicals, and materials research R&D. Its portfolio combines molecular modeling and simulation, laboratory informatics, AI-driven scientific data management, and contract research services used by pharmaceutical, biotechnology, consumer products, aerospace, automotive, and specialty chemicals organizations.

Product overview

BIOVIA, a brand of Dassault Systèmes (which acquired Accelrys in 2014), offers a comprehensive scientific software portfolio organized around the 3DEXPERIENCE BIOVIA platform — a unified, collaborative environment connecting all solutions from molecule to manufacturing. The core portfolio includes scientific data management and AI capabilities through BIOVIA Scientific AI; molecular modeling via BIOVIA Discovery Studio and Materials Studio; laboratory management via BIOVIA ONE Lab (spanning LIMS, ELN, and instrument management); data processing via Pipeline Pilot; and specialized solutions for formulation development, QC automation, biotherapeutics, and virtual twin experiences. Disciplines span Biosciences, Laboratory Informatics, Materials Science & Engineering, Regulatory Management, Scientific Informatics, and Quality Management.

Differentiator

Problem solved

Functional benefit

Products and services

• 3DEXPERIENCE BIOVIA Unified scientific informatics platform combining molecular modeling, simulation, laboratory informatics, and scientific data management on Dassault Systèmes' 3DEXPERIENCE platform for enterprise R&D.
• BIOVIA Discovery Studio

Quantifiable outcome

• Saved Pfizer scientists 5-7 hours per week through automated error checking and data collection
• +1 more outcomes

Named customers14 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature8 records

Partnerships

One partnership is on record.

• NVIDIAcoreTechnology or Integration · 1 January 2025Strategic partnership combining NVIDIA-accelerated AI inference with BIOVIA's scientific AI and modeling capabilities. Enables design of impossible therapeutics and high-performance materials within a collaborative 3D environment. Partnership focuses on next-generation AI-powered computational biology and molecular design.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Accelrys
• YouTubeyoutube.com/c/BIOVIA1
• Facebookfacebook.com/accelrys
• LinkedInlinkedin.com/company/accelrys
• Instagraminstagram.com/3dsbiovia

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accelrys